CYP19A1 and breast carcinoma: The updated Position Statement in June 2011 by Breast Cancer Deadline 2020 reads, “There is no current evidence that these drugs (tamoxifen, raloxifene and aromatase inhibitors) “prevent” breast cancer [69]”.